2007
Levemir® Early Clinical Experience Case Series
Mayerson AB. Levemir® Early Clinical Experience Case Series. Endocrinology And Metabolism Clinics Of North America 2007, 36: 45-52. PMID: 17881331, DOI: 10.1016/s0889-8529(07)80007-7.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsAgedAged, 80 and overDiabetes Mellitus, Type 2FemaleHumansHypoglycemic AgentsInsulinInsulin DetemirInsulin, Long-ActingMaleMiddle AgedUnited StatesConceptsInsulin detemirCase seriesDiscontinuation of treatmentMean weight lossLarge observational studiesType 2 diabetesDaily regimenFinal followTreatment discontinuationGlycemic controlTreatment initiationHypoglycemic episodesA1C valuesCase reportThird followObservational studyDetemirMean decreasePatientsSpecial interventionDoctor's officeWeight lossObservation periodDiscontinuationRegimen
2002
Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes
Hundal RS, Petersen KF, Mayerson AB, Randhawa PS, Inzucchi S, Shoelson SE, Shulman GI. Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. Journal Of Clinical Investigation 2002, 109: 1321-1326. PMID: 12021247, PMCID: PMC150979, DOI: 10.1172/jci14955.Peer-Reviewed Original ResearchMeSH KeywordsAdultAspirinBlood GlucoseCyclooxygenase InhibitorsDiabetes Mellitus, Type 2FemaleGlucose Tolerance TestHumansI-kappa B KinaseMaleMiddle AgedProtein Serine-Threonine KinasesConceptsAspirin treatmentInsulin resistanceTolerance testPlasma glucoseInsulin-stimulated peripheral glucose uptakeHigh-dose aspirin treatmentMixed meal tolerance testType 2 diabetic subjectsMixed-meal tolerance testType 2 diabetes mellitusHigh-dose aspirinWeeks of treatmentC-reactive proteinPeripheral glucose uptakeHyperinsulinemic-euglycemic clampType 2 diabetesPlasma insulin concentrationHepatic glucose productionFatty acid levelsDiabetes mellitusDiabetic subjectsTotal cholesterolGlucose toleranceInsulin clearanceTissue inflammationType 2 diabetes therapy
Mayerson AB, Inzucchi SE. Type 2 diabetes therapy. Postgraduate Medicine 2002, 111: 83-95. PMID: 11912999, DOI: 10.3810/pgm.2002.03.1140.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsAlpha-GlucosidasesBenzamidesBiguanidesDiabetes Mellitus, Type 2HumansHypoglycemic AgentsSulfonylurea CompoundsThiazolesThiazolidinedionesThe Effects of Rosiglitazone on Insulin Sensitivity, Lipolysis, and Hepatic and Skeletal Muscle Triglyceride Content in Patients With Type 2 Diabetes
Mayerson AB, Hundal RS, Dufour S, Lebon V, Befroy D, Cline GW, Enocksson S, Inzucchi SE, Shulman GI, Petersen KF. The Effects of Rosiglitazone on Insulin Sensitivity, Lipolysis, and Hepatic and Skeletal Muscle Triglyceride Content in Patients With Type 2 Diabetes. Diabetes 2002, 51: 797-802. PMID: 11872682, PMCID: PMC2995527, DOI: 10.2337/diabetes.51.3.797.Peer-Reviewed Original ResearchMeSH KeywordsAdipocytesAdipose TissueBlood GlucoseBody CompositionCalorimetry, IndirectDiabetes Mellitus, Type 2Fatty AcidsGlucose Clamp TechniqueGlycated HemoglobinGlycerolHumansHyperinsulinismInsulinKineticsLipidsLipolysisLiverMagnetic Resonance SpectroscopyMicrodialysisMiddle AgedMuscle, SkeletalOxidation-ReductionRosiglitazoneThiazolesThiazolidinedionesTriglyceridesConceptsPlasma fatty acid concentrationsMuscle triglyceride contentEffects of rosiglitazoneType 2 diabetesInsulin sensitivityPeripheral adipocytesTriglyceride contentRosiglitazone treatmentFatty acid concentrationsTwo-step hyperinsulinemic-euglycemic clampSkeletal muscle triglyceride contentType 2 diabetic subjectsInsulin-stimulated glucose metabolismWhole-body insulin sensitivityExtramyocellular lipid contentInsulin-responsive organHepatic triglyceride contentHyperinsulinemic-euglycemic clampAdipocyte insulin sensitivityDiabetic subjectsInsulin clampGlucose metabolismGlycerol releaseResponsive organSubcutaneous fat